Cellectar Biosciences (CLRB) Stock Price, News & Analysis

Company Overview

Cellectar Biosciences, Inc. is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma. In addition to its therapeutic pipeline, Cellectar has developed CLR 1501 and CLR 1502, fluorescent and near‐infrared imaging probes that enhance intraoperative tumor detection and surgical guidance. These imaging agents are intended to help surgeons distinguish cancerous tissue from healthy tissue in real time.

Founded in 2007 and headquartered in Madison, Wisconsin, Cellectar Biosciences conducts its research and development primarily in the United States. Preclinical and clinical studies have demonstrated the selective uptake and prolonged retention of its PDC compounds in tumor cells, supporting the potential of its platform across a range of oncologic indications. The company collaborates with academic centers and contract research organizations to advance its clinical programs.

Under the leadership of President and Chief Executive Officer Will Berry, Cellectar Biosciences is advancing its pipeline and engaging with regulatory agencies to support future product commercialization. The company continues to explore strategic partnerships and funding opportunities to further develop its PDC technology for both therapeutic and diagnostic applications in oncology.

Key Stats

• Today's Range: $2.61 to $2.70
• 50-Day Range: $2.23 to $2.83
• 52-Week Range: $2.20 to $6.52
• Volume: 56,234 shs
• Average Volume: 40,838 shs
• Market Capitalization: $25.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Cellectar Biosciences Stock Analysis - MarketRank™

Cellectar Biosciences scored higher than 65% of companies evaluated by MarketBeat, and ranked 382nd out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cellectar Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cellectar Biosciences has a consensus price target of $11.00, representing about 313.7% upside from its current price of $2.66.

Amount of Analyst Coverage

Cellectar Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cellectar Biosciences are expected to grow in the coming year, from ($2.39) to ($2.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellectar Biosciences is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellectar Biosciences is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cellectar Biosciences has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.25% of the float of Cellectar Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cellectar Biosciences has a short interest ratio ("days to cover") of 3.93, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellectar Biosciences has recently decreased by 12.34%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellectar Biosciences does not currently pay a dividend.

Dividend Growth

Cellectar Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.19

News Sentiment

Cellectar Biosciences has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Cellectar Biosciences this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for CLRB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.58% of the stock of Cellectar Biosciences is held by insiders.

Percentage Held by Institutions

16.41% of the stock of Cellectar Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 8/19/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CLRB
• CIK: 1279704
• Web: www.cellectar.com
• Phone: (608) 441-8120
• Fax: 608-441-8121
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cellectar Biosciences: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +313.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -185.35%
• Return on Assets: -115.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.66
• Quick Ratio: 6.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.16 per share
• Price / Book: 0.84

Miscellaneous

• Outstanding Shares: 9,450,000
• Free Float: 9,208,000
• Market Cap: $25.13 million
• Optionable: No Data
• Beta: 0.55